Clinical Presentation and Diagnosis

The American Urological Association notes that dysuria is a well-recognized symptom of interstitial cystitis/bladder pain syndrome (IC/BPS) and occurs commonly in affected patients, particularly in younger individuals at the time of diagnosis 1
The pain associated with urination in IC/BPS is distinct from infectious cystitis because urine cultures remain negative despite the presence of dysuria 1
IC/BPS dysuria persists for at least 6 weeks in the absence of documented urinary tract infection, which is a key diagnostic criterion 1, 2
Unlike bacterial cystitis, patients with IC/BPS may initially present with a single symptom such as dysuria, but subsequent cultures are consistently negative 1

Distinguishing IC/BPS Dysuria from Other Conditions

The dysuria is perceived as pain, pressure, or discomfort related to the urinary bladder, distinguishing it from urethritis which typically presents with urethral discharge 3

Always obtain urine culture to document negative results, as this is essential for IC/BPS diagnosis and excludes bacterial infection 2
Document the duration of symptoms—dysuria must be present for at least 6 weeks to meet diagnostic criteria 2
Assess for accompanying symptoms including pelvic pain, urinary frequency, urgency, and in women, dyspareunia 1
Behavioral modifications including avoidance of bladder irritants and stress management should be implemented first 4
Manual physical therapy is indicated for patients with pelvic floor tenderness, which commonly accompanies dysuria in IC/BPS 5, 3
Oral medications such as amitriptyline, cimetidine, or hydroxyzine may provide relief 6, 3
Pain management alone is insufficient—treatment must address the underlying bladder-related symptoms causing the dysuria 6, 4

The American Urological Association emphasizes that antimuscarinics should be used with extreme caution in patients with certain comorbidities, and cardiovascular instability represents a relative contraindication 7
Beta-3 agonists (mirabegron) would be preferred over antimuscarinics if an overactive bladder medication were needed, as they have fewer cardiovascular side effects, though the primary diagnosis here is IC/BPS, not OAB 7
The AUA/SUFU guidelines support combining behavioral therapy with pharmacotherapy for patients whose symptoms do not adequately respond to monotherapy 7

Antimuscarinic medications (such as trospium, oxybutynin, or tolterodine) are typically used for overactive bladder but carry significant risks in patients with hypotension, and can exacerbate hypotension and vertigo through their anticholinergic effects, making them unsuitable for this specific patient 7